- Home
- GLTO vs LKCO Comparison
GLTO vs LKCO Comparison
Compare GLTO & LKCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GLTO
- LKCO
- Stock Information
- Founded
- GLTO 2011
- LKCO 2009
- Country
- GLTO Denmark
- LKCO China
- Employees
- GLTO N/A
- LKCO N/A
- Industry
- GLTO Biotechnology: Pharmaceutical Preparations
- LKCO EDP Services
- Sector
- GLTO Health Care
- LKCO Technology
- Exchange
- GLTO Nasdaq
- LKCO Nasdaq
- Market Cap
- GLTO 6.5M
- LKCO 5.5M
- IPO Year
- GLTO 2020
- LKCO N/A
- Fundamental
- Price
- GLTO $4.51
- LKCO $1.76
- Analyst Decision
- GLTO Buy
- LKCO
- Analyst Count
- GLTO 1
- LKCO 0
- Target Price
- GLTO $10.00
- LKCO N/A
- AVG Volume (30 Days)
- GLTO 14.7K
- LKCO 27.9K
- Earning Date
- GLTO 03-07-2025
- LKCO 10-22-2024
- Dividend Yield
- GLTO N/A
- LKCO N/A
- EPS Growth
- GLTO N/A
- LKCO N/A
- EPS
- GLTO N/A
- LKCO N/A
- Revenue
- GLTO N/A
- LKCO $5,389,818.00
- Revenue This Year
- GLTO N/A
- LKCO N/A
- Revenue Next Year
- GLTO N/A
- LKCO N/A
- P/E Ratio
- GLTO N/A
- LKCO N/A
- Revenue Growth
- GLTO N/A
- LKCO N/A
- 52 Week Low
- GLTO $4.24
- LKCO $1.43
- 52 Week High
- GLTO $23.50
- LKCO $7.68
- Technical
- Relative Strength Index (RSI)
- GLTO 39.75
- LKCO 45.90
- Support Level
- GLTO $4.39
- LKCO $1.63
- Resistance Level
- GLTO $4.84
- LKCO $2.09
- Average True Range (ATR)
- GLTO 0.31
- LKCO 0.16
- MACD
- GLTO 0.00
- LKCO -0.02
- Stochastic Oscillator
- GLTO 26.73
- LKCO 26.00
About GLTO Galecto Inc.
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
About LKCO Luokung Technology Corp
Luokung Technology Corp is a spatial-temporal intelligent big data services company, as well as a provider of LBS for various industries in China. It has established city-level and industry-level holographic spatial-temporal digital twin systems and actively serves industries including smart transportation (autonomous driving, smart highway and vehicle-road collaboration), natural resource asset management (carbon neutral and environmental protection remote sensing data service), and LBS smart industry applications (mobile Internet LBS, smart travel, smart logistics, new infrastructure, smart cities, emergency rescue, among others).